Latest Media Releases

All A B C D E F G H I J K L M N O P Q R S T U V W X Y Z

Noxopharm: NOX66 Clinical Development Strategy for 2018 (ASX:NOX)

END OF YEAR GUIDANCE ON NOX66 CLINICAL DEVELOPMENT STRATEGY FOR 2018 3 current Phase 1 studies 4 multinational Phase 2/Phase 3 DARRT studies in 2018 Aim to identify nature of Phase 3 studi...read more

Noxopharm, Open Briefing Presentation - December 6, 2017 (ASX:NOX)

Oncology NOX66 Idronoxil (lipophilic form) ABOUT IDRONOXIL Multiple anti-cancer actions 1. Inhibits DNA repair (inhibits PARP-1, topoisomerases 1 and 2) 2. Promotes anti-tumour immunity...read more

Noxopharm: Compassionate Use of NOX66 in Patients (ASX:NOX)

Sydney, 4 December 2017: Noxopharm Limited (NOX:ASX) has become aware of information circulating in the market about an abscopal anti-cancer response in a patient receiving the Company’s experim...read more

Noxopharm Announces Promising Interim Clinical Data for NOX66 (ASX:NOX)

- Patients with metastatic, late-stage cancers - 10 of 11 patients showing no disease progression following 3-months treatment with NOX66 in combination with low-dose carboplatin - Well-tolerate...read more

Noxopharm Announces First Patient Treated in St Vincent's Hospital, Sydney Radiotherapy Study (ASX:NOX)

- Combination of NOX66 + internal radiotherapy - Late-stage prostate cancer patients - Safety and efficacy study 16 November 2017, Sydney: Noxopharm (ASX:NOX) today announces the treatment of...read more

Noxopharm Announces Collaboration with UNSW Confirms Drug Designed to Help Stroke Victims (ASX:NOX)

Loss of brain function after stroke or concussion mainly due to secondary death of brain cells NYX-104 confirmed as inhibitor of this secondary process in animals NYX-104 being developed as a...read more

Noxopharm, Open Briefing Corporate Presentation (ASX:NOX)

NOX: Unique opportunities Idronoxil - Kills all forms of cancer cells - Sensitises to chemotherapy - Sensitises to radiotherapy To view Presentation please download PDF attached:

Noxopharm Announces Australian NOX66 and Radiotherapy Study Opens (ASX:NOX)

AUSTRALIAN NOX66 - RADIOTHERAPY STUDY OPENS late-stage prostate cancer novel attempt to sensitise cancers to low-dose radiation aim to achieve shrinkage of both irradiated and non...read more

Noxopharm announces establishment of Nyrada Inc. (ASX:NOX)

ESTABLISHMENT OF NYRADA INC. NOX establishes subsidiary Nyrada Inc. to develop non- oncology drug IP Nyrada is a New York-based drug discovery and development company Initial 3 drug assets in ...read more

Noxopharm Announces Positive Clinical Outcomes for NOX66 Reported at ESMO Conference (ASX:NOX)

- Patients with late-stage, metastatic cancers - NOX66 in combination with carboplatin - No toxicity associated with NOX66 - Stabilisation of disease process Sydney, 12 September 2017: Nox...read more

Noxopharm, CEO Interview Explains Recent Brain Cancer Announcement (ASX:NOX)

Noxopharm (NOX:ASX) today releases a videotaped FNN interview with CEO, Dr Graham Kelly, on the subject of an announcement made to the market on 29 August 2017. That earlier announcement related to...read more

Noxopharm Announces Important Brain Cancer Findings for NOX66 Program (ASX:NOX)

- Idronoxil enhances anti-cancer effect of main cancer drug on primary brain cancers - Idronoxil able to kill highly drug-resistant brain cancer cells - Effect of idronoxil unaffected by express...read more

Noxopharm Announces $5.5 Million Raised to Advance Clinical Program (ASX:NOX)

Noxopharm Limited (ASX:NOX) is pleased to announce the placement of 16,666,667 fully paid ordinary shares to sophisticated and institutional investors at a price of $0.33 per share, raising a total of...read more

Noxopharm, Corporate Presentation August 2017 (ASX:NOX)

Objective 1 To bring to market by 2022 a drug (NOX66) that: - sensitises most forms of cancer to radiotherapy and chemotherapy - delivers improved survival outcomes for most cancer patients ...read more

Noxopharm Announces CEO Interview with Finance News Network - Singapore and Hong Kong Roadshow July 2017 (ASX:NOX)

SYDNEY 25 July 2017 : Noxopharm Limited (ASX:NOX) provides an interview with CEO, Dr Graham Kelly, produced for the Company’s Singapore and Hong Kong Roadshow 26-28 July 2017. For further i...read more

Viewing: 121 - 135 of 169 Previous | Next